Xenon Pharmaceuticals Inc.
XENE · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.25 | 8.52 | -3.16 | -1.53 |
| FCF Yield | -2.61% | -2.34% | -1.80% | -1.69% |
| EV / EBITDA | -25.05 | -34.81 | -38.25 | -40.96 |
| Quality | ||||
| ROIC | -14.52% | -10.12% | -9.56% | -9.06% |
| Gross Margin | 0.00% | 100.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.79 | 0.76 | 0.95 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,957,333.82% | 284.44% | 123.92% | -100.00% |
| Free Cash Flow Growth | -4.37% | -11.83% | -6.63% | -51.31% |
| Safety | ||||
| Net Debt / EBITDA | 1.35 | 1.48 | 1.74 | 1.07 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -681.84 | 103.79 | -668.31 | -729.82 |